GlassScriptPhysician profile
Paul H Janda
NPI 1497924468
$15,641.78
in general payments reported to CMS, 2019-2025
67 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $445 · 2021: $1,473 · 2022: $3,825 · 2023: $3,021 · 2024: $2,620 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,783 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,783.21 |
| Education | $287.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,264.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,483.62 | 2019-2025 | |
| Cadwell Industries, INC | $1,185.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $955.93 | 2019-2025 | Austedo Xr, Austedo |
| Ucb, INC. | $622.39 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Pfizer INC. | $571.74 | 2019-2025 | |
| Amgen INC. | $481.06 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $451.61 | 2019-2025 | Enspryng, Ocrevus, Evrysdi |
| Allergan, INC. | $448.78 | 2019-2022 | |
| Emd Serono, INC. | $444.49 | 2019-2024 | Mavenclad |
| Celgene Corporation | $384.56 | 2020-2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $280.23 | 2019-2024 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $279.67 | 2020-2025 | Ingrezza, Ongentys |
| Horizon Therapeutics Plc | $261.47 | 2021-2023 | Uplizna |
| Argenx US, INC. | $255.46 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Janda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.